CellMiner and CellMiner Cross Database (CDB) function to integrate datasets and allow comparison of genomic, molecular and pharmacological data within multiple cancerous cell line sets, including the i) National Cancer Institute's NCI-60, ii) Cancer Cell Line Encyclopedia (CCLE), iii) Genomics of Drug Sensitivity in Cancer (GDSC), iv) Cancer Therapeutics Response Portal (CTRP), v) NCI/DTP small cell lung cancer (SCLC), and vi) the NCI Almanac (with two-drug combinations).
CellMiner facilitates pharmacogenomics analyses for the NCI-60. It currently includes 24 downloadable data sets. CellMinerCDB facilitates pharmacogenomics analyses for the NCI-60, CCLE, GDSC, CTRP, NCI/DTP SCLC, and NCI Almanac cell line sets. It currently includes 26 downloadable data sets. Both provide multiple tools query functions, and supportive information and are described in detail in their respective urls.
CellMiner contains data for the NCI-60, including the most extensive public set of cell line molecular and drug activity data. The drug data is generated by the NCI Developmental Therapeutics Program https://dtp.cancer.gov. These include 4.0×109 gene alteration versus compound activity combinations. CellMinerCDB contains data for the CCLE, GDSC, and CTRP, which provide substantially increased cell line numbers and tissue of origin types. These include 7.2×107 gene alteration versus compound activity combinations. Taken together, the two web-applications provide partially overlapping complimentary data and functionalities. The data types available for each cell line set varies, as well as the numbers of cell lines that overlap between cell line sets. There are 60 cell lines for the NCI-60, 67 for the NCI/DTP SCLC, 1,036 for the CCLE, 1,080 for the GDSC, and 823 for CTRP. Using the overlaps that exist between these cell line sets, one may fill in data gaps, extend analyses, and assess quality and reliability.
Exploration of pharmacological responses in cancers is facilitated by the rich and unmatched set of data and functionalities made available within these tools, and it serves as a base for translational analysis.
The National Cancer Institute, USA.
The National Cancer Institute, USA.
All authors have declared no conflicts of interest.